Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Symbol: ZURA) is a clinical-stage biotechnology company dedicated to advancing medical science by developing novel treatments for immune and inflammatory disorders. The company's leading asset, ZB-168, is an anti-IL7Rα inhibitor with promising applications in conditions like alopecia areata and other inflammatory diseases. ZB-168 targets the IL7 and TSLP biological pathways, which are key drivers in these conditions, aiming to provide a new therapeutic option where few exist.
Zura Bio is committed to building a robust portfolio of therapeutic indications for ZB-168. The company is actively focused on demonstrating the drug’s efficacy, safety, dosing convenience, and mechanism of action, starting with alopecia areata. This effort is supported by Phase 1b data in type 1 diabetes, which has shown a favorable safety profile and strong biological rationale.
Headquartered in London, UK, Zura Bio operates with a global team of experts based in both the UK and the USA. The company leverages cutting-edge research and development to tackle some of the most challenging health issues today.
As a multi-asset company, Zura Bio is well-positioned to make significant contributions to the field of biotechnology. Through strategic partnerships and a commitment to innovation, the company aims to bring life-changing therapies to patients who need them the most.
- Core Business: Biotechnological research and development focused on immune and inflammatory disorders.
- Leading Product: ZB-168, an anti-IL7Rα inhibitor for alopecia areata and other inflammatory diseases.
- Headquarters: London, UK.
- Global Presence: Team members located in the UK and USA.
Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.
Zura Bio presented data on tibulizumab (ZB-106) at EULAR 2024, demonstrating promising results in treating Sjogren's syndrome and rheumatoid arthritis (RA). The Phase 1 study showed tibulizumab was well-tolerated and effective in neutralizing IL-17A and BAFF, reducing B cell counts and modulating inflammatory mediators in 25 participants. Preclinical data in a RA mouse model indicated significant reductions in disease scores and inflammation when both IL-17A and BAFF were inhibited. The studies suggest tibulizumab's potential as a dual-pathway treatment for autoimmune diseases.
Zura Bio, a clinical-stage immunology company, has formed a Scientific Advisory Board (SAB) with experts in rheumatology, dermatology, and immunology. The board includes Johann Gudjonsson, Dinesh Khanna, Ajay Nirula, Michael Weinblatt, and Steven Ziegler. This initiative aims to advance their clinical and translational science efforts, particularly in Phase 2 clinical development for systemic sclerosis and hidradenitis suppurativa. The SAB will also focus on the roles of BAFF and IL-17A in autoimmune and inflammatory diseases, enhancing Zura Bio's research and clinical trials.
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to illustrate the antibody's capacity to inhibit both pathways in a single therapy, potentially broadening its clinical applications across various autoimmune diseases. Zura Bio also disclosed timelines for Phase 2 trials: systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025.
Zura Bio, a clinical-stage immunology company with a focus on novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced participation in two June investor conferences. Chief Scientific Officer Michael Howell will attend one-on-one meetings at the Jefferies Global Healthcare Conference on June 6, 2024, in New York. CEO Robert Lisicki will participate in a panel discussion on dermatological disorders and hold one-on-one meetings at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York. These events aim to strengthen investor relations and provide insights into Zura Bio's innovative clinical programs.
Zura Bio reported financial results for Q1 2024, ending with $89.8M in cash and closing an oversubscribed $112.5M private placement in April. The company appointed a new CEO and CMO and is on track to start Phase 2 studies for SSc and HS. Cash runway extended through 2027. R&D expenses decreased, while G&A expenses increased. Net loss reduced. Anticipated milestones include Phase 2 trials for ZB-106 and monitoring of ZB-168 and ZB-880.
FAQ
What is the current stock price of Zura Bio (ZURA)?
What is the market cap of Zura Bio (ZURA)?
What does Zura Bio Limited do?
What is Zura Bio's leading product?
What is ZB-168?
Where is Zura Bio headquartered?
Does Zura Bio have a global presence?
What are the current projects of Zura Bio?
Who are Zura Bio's target patients?
What is the significance of the Phase 1b data for ZB-168?
What is the strategic focus of Zura Bio?
How does Zura Bio contribute to biotechnology?
